文献速递贫血与红细胞疾病

铁缺乏与HbSS和HbSC患者炎症及溶血水平降低相关,并与HbSC患者临床入院减少相关

Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC.
PubMed 文献 · Br J Haematol · 2025-12-14

回顾性分析2008至2020年国王学院医院512例镰状细胞病患者的临床与实验室数据,按铁蛋白水平分为低铁蛋白血症、正常铁蛋白血症和高铁蛋白血症三组。在HbSC患者中,低铁蛋白血症与年住院次数和住院天数显著减少相关;在HbSS患者中虽未见此现象,但低铁蛋白血症与较低的溶血和炎症标志物相关,两组总血红蛋白或促红细胞生成素均无差异。

要点

  • HbSC患者中低铁蛋白血症与年住院次数和住院天数显著减少相关。
  • HbSS患者中低铁蛋白血症与较低的溶血和炎症标志物相关,但住院未见减少。
  • 低铁蛋白水平未与贫血加重相关,提示红细胞存活改善。

核心结论

  • 铁缺乏可能降低HbSS和HbSC患者的炎症和溶血,临床获益在HbSC中可显现。
  • 低铁蛋白水平未与贫血加重相关,提示红细胞存活改善。
  • 限制性红细胞生成在某些情况下可能对镰状细胞病患者有益。

研究设计与样本

  • 回顾性分析2008至2020年国王学院医院512例镰状细胞病患者(408例HbSS,104例HbSC)的临床和实验室数据。
  • 门诊数据取自既往90天内未输血或未使用羟基脲(羟基脲)的患者。
  • 患者按铁蛋白水平分为低铁蛋白血症(<45 μg/L)、正常铁蛋白血症(45-800 μg/L)和高铁蛋白血症(>800 μg/L)三组。

主要发现

  • HbSC患者中,低铁蛋白血症组较正常铁蛋白血症组年住院次数和住院天数显著减少。
  • HbSS患者中未见住院减少,但低铁蛋白血症与较低的溶血和炎症标志物相关。
  • 两组总血红蛋白或促红细胞生成素均无差异。
  • HbSS患者中,低铁蛋白血症组血红蛋白F显著低于正常铁蛋白血症组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Evidence suggests that iron deficiency may reduce sickle cell disease (SCD) complications by decreasing sickle haemoglobin polymerization through reduced red cell haemoglobin concentration. The aim is to investigate the effects of iron deficiency in SCD patients. We reviewed clinical and laboratory data from 512 patients (408 HbSS, 104 HbSC) at King's College Hospital (2008-2020). Outpatient data were collected from patients with no blood transfusions or hydroxyurea (hydroxycarbamide) use in the prior 90 days. Patients were categorized as hypoferritinaemic (<45 μg/L), normoferritinaemic (45-800 μg/L) or hyperferritinaemic (>800 μg/L) and analysed for laboratory markers and clinical complications. In HbSC patients, hypoferritinaemia was associated with significantly fewer hospital admissions and inpatient days per year compared to normoferritinaemia. Although this was not seen in HbSS patients, hypoferritinaemia correlates with lower haemolysis and inflammation markers, with no differences in total haemoglobin or erythropoietin in both groups. In HbSS patients, haemoglobin F was significantly lower in hypoferritinaemic compared to normoferritinaemic patients. Iron deficiency may reduce inflammation and haemolysis in both HbSS and HbSC, with clinical benefits demonstrable in HbSC. Low ferritin levels were not associated with increased anaemia, suggesting improved red cell survival. Iron-restricted erythropoiesis may benefit SCD patients in certain circumstances.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Villaboni S, Stuart-Smith S, De Kreuk A, et al. Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC. Br J Haematol. 2025. PMID: 41392388. doi:10.1111/bjh.70262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。